Production (Stage)
Sharp Therapeutics Corp.
SHRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2,787.84% | 0.00% | -- | -- | -30.89% |
| Total Depreciation and Amortization | 8.03% | 0.00% | -- | -- | 61.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 321.38% | 0.00% | -- | -- | 62.11% |
| Change in Net Operating Assets | 22.66% | 0.00% | -- | -- | -156.96% |
| Cash from Operations | -17.66% | 0.00% | -- | -- | -28.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00% | -- | -- | -- |
| Cash from Investing | -- | 0.00% | -- | -- | -- |
| Total Debt Issued | -- | 0.00% | -- | -- | -- |
| Total Debt Repaid | 70.31% | 0.00% | -- | -- | 0.00% |
| Issuance of Common Stock | -- | 0.00% | -- | -- | -58.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00% | -- | -- | -- |
| Cash from Financing | -101.78% | 0.00% | -- | -- | -10.00% |
| Foreign Exchange rate Adjustments | -966.67% | 0.00% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -190.33% | 0.00% | -- | -- | -624.93% |